相关实验视频

Updated: Jun 23, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

用针对p53突变体的抗体重塑抗瘤免疫力

Dafei Chai¹, Junhao Wang², Chunmei Fan²

¹Department of Medicine, Section of Epidemiology and Population Sciences, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA. Dafei.Chai@bcm.edu.

Journal of hematology & oncology

|June 17, 2024

概括

新的单克隆抗体 (mAbs) 针对p53 E285K突变,通过增强免疫细胞透来显示抗瘤作用. 这种由LNP提供的疗法为特定癌症类型提供了精准医学方法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

在癌症中,TP53基因经常发生突变,但缺乏有效的向疗法.
特定的p53突变,如E285K,提供治疗点.
开发针对突变p53的药物对于癌症治疗至关重要.

研究的目的:

开发和评估针对p53 E285K突变的新型单克隆抗体 (mAbs).
评估编码这些mAbs的LNP输送DNA质粒的有效性.
研究由这些向mAbs.诱导的抗瘤机制和免疫反应.

主要方法:

对p53 E285K突变特异的单克隆抗体 (mAbs) 的开发.
使用脂质纳米粒子 (LNPs) 编码mAbs的DNA等离子体的输送.
在体外和体内功能评估使用西斑,BLI,流细胞计和scRNA-seq.

主要成果:

通过LNP递送的p53 E285K-mAbs (IgG1格式) 显示出显著的抗瘤活性.
观察到CD8+ T,B和NK细胞透到瘤中的增强.
scRNA-seq揭示了免疫抑制的减少和抗瘤免疫信号的增加.

结论:

针对p53突变体的DNA编码,LNP传递的mAbs提供了一个精准医学策略.
IgG1 mAbs的有效性取决于TRIM21,而dIgA mAbs则依赖于PIGR.
这种方法对具有特定p53突变和相关受体表达的癌症具有前景.

关键词:

E285KK E285KKKK E285KKK E285KKK E285KKK E285KK E285KK E285KK E285KK E285KK E285KK E285KK E285K K 在IgG1的基础上,IgG1 单克隆抗体是一种单克隆抗体.突变的 p53 变种这是一条漫长的道路

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...